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Peptidylarginine deiminases (PAD) convert protein-bound arginine residues into citrulline residues in a Ca2þ ion-
dependent manner. Among the ﬁve isoforms (PAD1, 2, 3, 4, and 6) existing in rodents and humans, PAD2 is the
most widely expressed in both species, tissues, and organs. In order to study the mechanisms regulating the
expression of the human PAD2 gene, PADI2, we characterized its promoter region using transfected human ker-
atinocytes. A series of reporter gene constructions derived from the 2 kb region upstream of the transcription
initiation site deﬁned a minimal promoter sequence from nucleotides 132 to 41. This PADI2 region is GC-rich
and lacks canonical TATA and CAAT boxes. Investigation of cis-acting elements in the region, further deletion
analyses and electrophoretic mobility shift assays using specific antibodies revealed four Sp1-binding sites and
identiﬁed Sp1 and Sp3 as binding factors important for the promoter activity. These results suggest that Sp1/Sp3
cooperation may provide a mechanism to control the transcription of PADI2.
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Peptidylarginine deiminases (PAD; EC 3.5.3.15) are post-
translational modification enzymes that catalyze the con-
version of protein-bound arginine residues to citrulline res-
idues in the presence of Ca2þ ion (Rogers and Taylor, 1977;
Takahara et al, 1983). They are widely expressed in various
tissues of vertebrates (Kubilus and Baden, 1983; Takahara
et al, 1986). Mammal PAD are categorized into five isoforms
(PAD1, 2, 3, 4, and 6), based on their molecular weights,
substrate specificities, and tissue localization (Vossenaar
et al, 2002). PAD family members are encoded by five genes
(PADI1, 2, 3, 4, and 6), which are clustered on a single
chromosome locus, i.e. 1p35–36 in humans and 4E1 in mice
(Chavanas et al, 2004). PAD isoforms display largely related
amino-acid sequences, but different tissue-specific expres-
sions were revealed: PAD1 is mainly detected in mouse
epidermis and uterus (Terakawa et al, 1991), and in human
epidermis, thymus, prostate, and placenta (Guerrin et al,
2003); PAD2 is widely expressed in a variety of tissues (Ta-
kahara et al, 1989); PAD3 is mainly detected in the epider-
mis and hair follicles (Nishijyo et al, 1997; Rogers et al,
1997); PAD4 is essentially expressed in neutrophils,
eosinophils, and monocytes (Nakashima et al, 1999; Asa-
ga et al, 2001), and PAD6 (formerly known as ePAD in
mouse) in the ovary, testis, and peripheral blood leukocyte
(Wright et al, 2003; Chavanas et al, 2004).
Although their exact physiological function has not been
clarified, three PAD isoforms (PAD1, 2, and 3) were reported
to be expressed in human epidermis (Kanno et al, 2000;
Ishigami et al, 2002b; Guerrin et al, 2003), and a number of
proteins including keratin K1, K10, filaggrin, and trichohyalin
have been shown to be deiminated during the terminal
stages of epidermal differentiation (Harding and Scott,
1983; Senshu et al, 1995, 1996). When the epidermal gran-
ular cells differentiate to cornified cells, deimination of ker-
atin filaments/filaggrin complexes results in the degradation
of the latter to form a pool of free amino acids. This allows
the cornified layer to retain water against the desiccating
action of the environment (Harding and Scott, 1983). Oth-
erwise, deimination of trichohyalin facilitates the cytokera-
tin–trichohyalin cross-link in hair follicles (Tarcsa et al, 1996,
1997; Steinert et al, 2003). Deimination of a 70 kDa nuclear
protein was found to be associated with apoptotic events in
keratinocyte (Mizoguchi et al, 1998). Furthermore, with ep-
idermal differentiation and hair follicle development, the lev-
els of protein deimination were changed (Akiyama and
Senshu, 1999). Recently, it was demonstrated that proteins
were orderly deiminated in different layers of human epider-
mis during embryogenesis (Tsuji et al, 2003). An abnormally
decreased level of deiminated keratin K1 has also been
reported in the involved areas of the epidermis of psoriatic
patients (Ishida-Yamamoto et al, 2000). These studies
Abbreviations: EMSA, electrophoretic mobility shift assay; NHEK,
normal human epidermal keratinocytes; PAD, peptidylarginine dei-
minase
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suggest important roles of PAD1, 2, and 3 in human epider-
mal keratinization and morphogenesis.
The transcriptional regulation of PADI genes has not
been investigated at all until now, and the cis-elements and
binding factors essential for their expression are unknown.
Here, we report the identification of the proximal minimal
promoter sequence of PADI2 and cis-acting elements in-
volved in the regulation of its expression. Moreover, elect-
rophoretic mobility shift assay (EMSA) demonstrated that
Sp1 and Sp3 bound to the proximal promoter regulate the
expression of PADI2.
Results
PADI2 expression in cultured human cells To search for
an experimental model suitable to delineate its proximal
promoter and explore its transcriptional regulation in the
epidermis, the expression of PADI2 was analyzed by real-
time RT-PCR on total RNA isolated from different human
keratinocyte primary cultures and cell lines: normal hu-
man epidermal keratinocytes (NHEK) cultured under high
(1.2 mM) or low (0.15 mM) Ca2þ ion concentration, HaCaT,
and HeLa cells. As shown in Fig 1, PADI2 mRNA was de-
tected in all cell types, but with variable levels: lowest in
HeLa cells and highest in NHEK cultured under high Ca2þ
ion concentration. These cultured cells can therefore be
used to study the transcriptional control of the PADI2 gene.
Identiﬁcation of the transcription initiation site To find
the location of the transcription initiation site of PADI2,
RNase protection analysis was carried out. As shown in
Fig 2A, the sizes of the protected RNA segments were 167
nt in both of NHEK cultured under high Ca2þ ion (1.2 mM)
medium and HaCaT. Primer extension products from the
protected RNA segments indicated that the transcription
initiation site was 79 bp upstream of the translation initiation
codon (Fig 2B). The transcription initiation site quite agreed
with the size of the protected RNA in Fig 2A. Furthermore,
the nucleotide sequence around the transcription initiation
site matched well with that of the cap signal as found in the
majority of eukaryotic promoters (Bucher, 1990). Therefore
we determined the nucleotide ‘‘G’’, 79 bp upstream of the
translation initiation codon (ATG) as the transcription initi-
ation site of PADI2, and referred as þ 1.
Promoter activity of the 50-ﬂanking region of PADI2 in
cultured cells To define the minimal promoter of PADI2, its
50-flanking region (1947 to þ80) and deletion fragments
were cloned into the ﬁreﬂy luciferase reporter pGBasic vec-
tor. Each resulting recombinant plasmid was then transient-
ly transfected into NHEK, HaCaT, and HeLa cells, and the
luciferase activities were determined (Fig 3A). In order to try
to define the position of putative differentiation-responsive
elements within the promoter, NHEK were either incubated
in low or high Ca2þ ion-containing medium. High levels of
luciferase activity were observed in NHEK and HaCaT cells
transfected with pG21947/þ 80, whereas the activity was
low in HeLa cells. Moreover, the activity detected in NHEK
Figure 1
Expression of peptidylarginine deiminase type II gene (PADI2)
transcripts in primary human epidermal keratinocytes cultured in
high (1.2 mM: black bar) and low (0.15 mM: hatched bar) Ca2þ ion-
containing medium, and human keratinocyte cell lines HaCaT (gray
bar) and HeLa (dotted bar). Total RNA was obtained from semi-con-
fluent cell cultures. The relative PADI2 mRNA levels were determined in
cDNA samples by quantitative real-time PCR as described in Materials
and methods. The indicated relative gene expression shows expression
levels that were normalized by glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) expression as a standard. Bars represent the mean
 SD of four separate experiments.
Figure2
Determination of the peptidylarginine deiminase type II gene (PAD-
I2) transcription start site. RNase protection analysis was performed
on 30 mg of total RNA from normal human epidermal keratinocytes
(NHEK) cells (lanes 2 and 5) cultured in high Ca2þ ion-containing (1.2
mM) medium and HaCaTcells (lanes 3 and 6). As control, 30 mg of tRNA
from salmon was used (lanes 1 and 4). (A) The protected RNA segments
were detected with a 167 nt band (indicated with an arrowhead) using
biotin-labeling method. A sequence reaction of pT7-PAD2 for ‘‘T’’ with
dUTP biotin-labeled was used as molecular weight marker (lane M). (B)
Primer extensions were performed on using the protected RNA seg-
ments as template and FITC-labeled primer described in Materials and
Method. The extension products were analyzed by electrophoresis in
denaturing polyacrylamide gels alongside an adjacent DNA sequencing
reaction using the same primer. The primer extension product is indi-
cated with filled arrowhead.
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was higher when the cells were cultured in high Ca2þ ion
concentration. These results were consistent with the ex-
pression of PAD2 mRNA in the same cells, as analyzed by
real-time RT-PCR (Fig 1). As shown in Fig 3A, relative lucif-
erase activities of deletion plasmids were kept at a high
level until the deletion proceeded to 132 bp. Further de-
letion to 41 bp sharply reduced the luciferase activity in
every cell type. These results suggested the presence of the
minimal promoter of PADI2 at 132/þ 80. Furthermore,
among the different constructs, the plasmid containing the
fragment 435/þ 80 showed the highest luciferase acti-
vity when expressed within NHEK. Luciferase activity de-
creased when the fragment was longer, suggesting the
presence of a suppressor activity in the upstream 1080/
435 region. Deletion of the 435/132 region led to a
decrease in reporter gene activity, also suggesting the pos-
sibility of a weak enhancer activity in this region. Since
these effects were only observed in NHEK cells, cell-spe-
cific cis-acting factor(s) might function in these regions.
Figure 3B shows the nucleotide sequence of the minimal
promoter of PADI2 that has a high GþC content (78%).
Match program using TRANSFAC 6.0 matrices revealed
that this region lacks canonical TATA and CAAT boxes (even
if an unusual CCACT box was observed), but contains sev-
eral putative binding sites for transcription factors such as
Sp1 (Fig 3B).
Identiﬁcation of potential cis-elements involved in PAD-
I2 gene regulation In order to further determine potential
cis-element of the minimal promoter involved in the tran-
scriptional control of the expression of PADI2, we con-
structed a new series of deletion mutants, which were
Figure 3
Identification and characterization of
the minimal promoter region of pep-
tidylarginine deiminase type II gene
(PADI2). (A) Identification of the minimal
promoter of PADI2. Normal human epi-
dermal keratinocytes (NHEK) cultured in
high (black bar) and low (hatched bar)
Ca2þ ion-containing medium; HaCaT
(gray bar) and HeLa (dotted bar) cells
were transfected with the indicated con-
structs and assayed for luciferase activity
after 48 h. The numbers given to the con-
structs indicate the 50- and 30-end of the
50-flanking region of PADI2, position num-
bered þ 1 corresponding to the first base
of the transcription initiation nucleotide.
Luciferase activity is expressed as a fold
increase over promoterless vector, pGBa-
sic (set as 1). Values were normalized for
transfection efficiency by cotransfection
with the Renilla expression plasmid, and
expressed as means  SD of four sepa-
rate experiments. (B) Sequence and pu-
tative transcription factor binding sites of
the minimal promoter of PADI2. Number-
ing of the nucleotides begins with the
transcription initiation nucleotide as þ1.
The arrows indicate the transcription ini-
tiation sites determined by RNase protec-
tion assay as shown in Fig 2. Potential
transcription factor binding sites predict-
ed by the Match program (Matrix groups:
vertebrates; Cut-offs: core similarity 1.0
and matrix similarity 0.95) are underlined.
(C) Characterization of the transcription
binding sites in the PADI2 promoter. The
schematic diagram of serial deletion con-
structs of the PADI2 promoter and their
luciferase activities in NHEK cultured in
high (black bar) and low (hatched bar)
Ca2þ ion-containing medium is shown.
The numbers given to the constructs in-
dicate the 50- and 30-end of the PADI2
promoter-flanking region. The nucleotide
sequences of putative transcription bind-
ing sites, which are targeted, are shown
on the constructs. Values were corrected
for transfection efficiency by contrans-
fection with the Renilla expression plasm-
id, and expressed as means  SD of four
separate experiments.
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transiently transfected into NHEK cultured under low or high
Ca2þ ion concentrations. The luciferase activities observed
in NHEK cultured in both conditions gradually decreased
with the successive deletions of the putative Sp1 binding
sites (Fig 3C). When all the binding sites were deleted
(pG241/þ 80), the promoter activity was almost com-
pletely abolished. Thus, all four Sp1 binding sites of the
promoter region between 132 and 41 bp seem to be
essential cis-elements for PADI2 transcription, whereas the
GATA-2 binding site seems to have no effects.
Binding of Sp1 and Sp3 to the PADI2 promoter re-
gion The ability of these potential Sp1 binding sites to ac-
tually bind Sp1 and/or Sp1-family factors was analyzed by
EMSA performed with nuclear extracts from NHEK, HaCaT,
and HeLa cells and 32P-labeled double-stranded oligonuc-
leotides. Probes 137/98 and 66/36 encompassed
the two distal and the two proximal putative Sp1 binding
sites, respectively, whereas no putative transcription factor
binding motifs were found in the sequence corresponding
to probe 99/67 (Fig 3B). In agreement, no retarded
bands were observed using the later probe and nuclear
extracts from any of the cell types (data not shown). EMSA
using probe 137/98 revealed three major protein com-
plexes. Their relative ratios were almost similar when com-
paring the extracts of Hela, HaCaT, and NHEK, but their
intensity seemed to be higher when using extracts of NHEK.
The complex with the lowest mobility were the more abun-
dant (Fig 4A, lanes 1–4). DNA–Sp1 complexes were report-
ed to have a slightly lower mobility than DNA–Sp3 complex
(Hagen et al, 1994). Moreover, Sp3 is usually expressed as
both a full-size and an N-terminal truncated form without a
complete DNA binding (Suske, 1999). Therefore, the up
band may correspond to Sp1–DNA complexes, the inter-
mediate band to Sp3–DNA complexes, and the fastest mi-
grating band to truncated-SP3–DNA complexes (indicated
by Sp30 in Fig 4). Alternatively, since the oligonucleotide
contains two Sp-binding sites, the two lower bands may
correspond to Sp3 bound to either one or two of the sites.
Super-shift analyses performed with nuclear extracts of
NHEK incubated in the presence of either anti-Sp1 or anti-
Sp3 antibodies demonstrated that Sp1 and Sp3 are really
Figure 4
Binding of Sp1 and Sp3 to the cis-acting elements of the peptidylarginine deiminase type II gene (PADI2) promoter. Electrophoretic mobility
shift assay (EMSA) was performed using synthetic oligonucleotides corresponding to two regions containing putative Sp1 binding elements, and
nuclear extracts (4 mg of protein) of HeLa (lane 1), HaCaT (lane 2), and normal human epidermal keratinocytes (NHEK) cultured in low (lane 3) and
high (lanes 4–6) Ca2þ ion-containing medium. For supershift assays, EMSA was performed using either anti-Sp1 (lane 5) or anti-Sp3 (lane 6)
antibody and nuclear extracts of NHEK cultured in high Ca2þ ion-containing medium. Lane 7 shows the EMSA with only the labeled probe. Panels A
and B show EMSA using the labeled probes 137/98 and 66/36, respectively. Sequences of the probes used are given in Table I. The two
upper bands correspond to Sp1- and Sp3-DNA complexes, and the lower band (Sp30) corresponds probably to a complex involving an N-terminal
truncated form of Sp3.
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involved in the complexes (Fig 4A, lanes 5 and 6). Similar
experiments performed with the probe 66/36, contain-
ing the two other Sp1 binding motifs, also revealed three
retarded bands that contain Sp1 and Sp3, as shown by
super-shift and disappearance of the corresponding bands
induced by the addition of antibodies to Sp1 and Sp3 (Fig
4B). In this case, the Sp1–DNA complexes were clearly
more abundant when using extracts of NHEK than the other
cell extracts. These results suggest that the transcription of
PADI2 may be controlled by the ratio of Sp1/Sp3.
Discussion
Since PAD2 is expressed widely but at different levels in a
variety of tissues and organs, it is possible that ubiquitously
expressed transcription factors are responsible for the wide
basal expression of PAD2 mRNA, whereas tissue-specific
factors account for the different levels observed in different
tissues. Although the exon–intron organization of PADI2 has
been described, the promoter region and mechanisms that
govern its transcription were unknown prior to the results
presented here. We identified a transcription initiation site,
we mapped its minimal promoter, at least in keratinocyte
primary cultures and cell lines, to the region 132/þ80,
and identified Sp1 and Sp3 as the cis-acting factors re-
sponsible for its basal transcription. This proximal 50-flank-
ing region of PADI2 was shown to lack a TATA box and a
canonical CAAT box, as many other genes, but to contain
some typical eukaryotic promoter elements including a Cap
site and a high GþC content. The presence of potential
regulatory elements in the region was confirmed by func-
tional reporter gene assays using transfected NHEK. We
found that four canonical GC boxes markedly enhance the
transcription. Using EMSA and super-shift analyses, we
demonstrated that both Sp1 and Sp3 bind to the boxes.
Sp1 and Sp3 were identified as ubiquitous transcription
factors implicated in the constitutive expression of several
genes. However, Sp3 binds GC boxes with different affin-
ities, its fixation being cell and promoter specific (Birnbaum
et al, 1995; Kennett et al, 1997; Philipsen and Suske, 1999;
Suske, 1999). Moreover, Sp3 can either activate or repress
promoter activity, depending on the individual promoter and
cell line used (Hagen et al, 1994; Udvadia et al, 1995). In
addition, the ratio of Sp1 to Sp3 in the cell may be important
in the regulation of transcription (Apt et al, 1996; Suske,
1999). Neighboring Sp1 binding sites can also frequently act
synergistically in regulating transcription. Such a cluster of
Sp proteins appears to stabilize transcription initiation com-
plexes (Chen et al, 2000). Since the GC boxes in the PADI2
promoter are overlapping or tightly clustered, the Sp pro-
teins may interact with each other and display cooperative
binding in regulating the gene. In our assays, the ratio of
Sp1/Sp3 bounded to the GC boxes of the PADI2 minimal
promoter seemed to parallel the transcriptional activity of
the endogenous PADI2 promoter, i.e., the higher was the
expression detected by real-time RT-PCR, higher was the
relative importance of Sp1–DNA/Sp3–DNA complexes ob-
served in EMSA experiments. This was particularly evident
for the two GC boxes close to each other and located near
the transcription start site in the position 65/41 (Fig 3B).
Altogether, these data suggest that the ratio of Sp1/Sp3
could provide a basal mechanism to control the transcrip-
tion of PADI2.
Induction of terminal differentiation of epithelial cells is a
complex process involving the regulation of many genes,
including those directly responsible for cell cycle withdraw-
al, growth arrest, and keratinization. The genes being turned
on and off at specific times during the differentiation proc-
ess result in the morphologic changes of epithelial cells.
Sp1 was reported to be involved in the regulation of the
terminal expressed genes during the differentiation process,
such as keratins (K3, K5, K16, K18), loricrin, involucrin, and
transglutaminase 3 (Lee et al, 1996; Eckert et al, 1997; Jang
and Steinert, 2002). Moreover, in this study, Sp1 was dem-
onstrated to play a central role in transcriptional regulation
of PADI2. These facts suggest that PADI2 was co-regulated
by Sp1 with other genes during the differentiation process.
Furthermore, PAD2 was co-expressed in the human epi-
dermis with PAD1 and PAD3 (Kanno et al, 2000; Ishigami
et al, 2002b; Guerrin et al, 2003), strongly suggesting that
these enzymes manifest discrete functions and substrate
specificities. In addition, a number of proteins were dei-
minated by PAD during the terminal stages of epidermal
differentiation, which were important for the morphologic
changes of epithelial cells (Harding and Scott, 1983; Senshu
et al, 1995, 1996). Therefore, our findings strongly support
the hypothesis that PADI2 expression is crucial for terminal
differentiation of epithelial cells, and co-regulated with
group genes by Sp1.
PAD2 is the only type of PAD expressed in the brain
where it is particularly abundant in the gray matter and
hypothalamus (Kubilus and Baden, 1983; Ishigami et al,
2002a). In addition, the amount of PAD2 in rodent uterus
(Takahara et al, 1989) and female pituitary (Senshu et al,
1989) shows estrous cycle-dependent fluctuations. The in-
teraction of a neurospecific POU protein such as N Oct-3
(Blaud et al, 2004) or estrogen receptor such as ERa
(Jacobson et al, 2003) on the promoter of PADI2 might be a
key issue in the regulation of this specific expression.
Our data on the expression of the PADI2 in keratinocytes
are the first study on the regulatory factors involved in the
transcription of this gene family. This may open the way for
the regulation of PAD expression, in particular of PAD2,
which is suspected to be involved in multiple sclerosis
(Moscarello et al, 2002; Nicholas et al, 2004).
Materials and Methods
Cell cultures NHEK were obtained from Clonetics (San Diego,
California), and cultured in a serum-free keratinocyte growth me-
dium (KGM2; Clonetics) with either 0.15 mM (proliferating condi-
tions) or 1.2 mM Ca2þ ion (differentiating condition), as described
previously (Hennings et al, 1980). The immortalized keratinocyte
line HaCaT, a generous gift of Prof. N. Fusenig (Heidelberg, Ger-
many), was grown in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco-BRL, Rockville, Maryland) supplemented with 5% fetal bo-
vine serum (FBS; HyClone Laboratories, Logan, Utah). HeLa cells
were obtained from the Health Sciences Research Resources
Bank (Osaka, Japan) and maintained in DMEM with 10% FBS. All
of the cells were incubated in humidified incubators at 371C and
5% CO2. After 70%–80% confluence, the cells were collected for
subculture or used for transient transfection.
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Analysis of the expression of PADI2 in cultured cells Tran-
scription level of PADI2 was analyzed by real-time RT-PCR. Total
RNA was extracted from the cultured cells with an RNeasy Protect
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. Real-time RT-PCR analysis was performed using the
SuperScript III Two-step qRT-PCR with SYBR Green Kit (Invitrogen,
Carlsbad, California) and iCycler IQ detection system (Bio-Rad,
Hercules, California). The relative expression values (x) of PADI2
in cultured cells were calculated using the following formula: x¼
2DCt, where DCt represents the difference between the Ct values
(mean threshold cycle) of PADI2 and the reference gene (glycer-
aldehyde-3-phosphate dehydrogenase: GAPDH). Primer sequenc-
es for real-time RT-PCR studies were as follows: PADI2 forward
primer 50-TGAAGCACTCGGAACACGT-30 (corresponding to nuc-
leotide position 189–207 of the human PAD2 complementary DNA
(cDNA), GenBank/EMBL/DDBJ accession number AB030176), re-
verse primer, 50-TTGTCACTGCTGGCCTCG-30 (position 322–339);
GAPDH forward primer 50-CATGTTCCAATATGATTCCAC-30 (posi-
tion 187–207 of the human GAPDH cDNA, accession number
M33197), reverse primer, 50-CCTGGAAGATGGTGATG-30 (position
271–287). The amplification program consisted of denaturation at
951C for 3 min, followed by 50 cycles at 951C for 30 s and at 591C
for 30 s using a two-step protocol.
Cloning of the 50-ﬂanking region of PADI2 Based on the nuc-
leotide sequences of human PADI genes (accession number
AJ549502), the 50-flanking region of PADI2 was amplified by PCR
from human genomic DNA (BD Biosciences, Palo Alto, California)
as a template and a pair of specific primers: forward, 50-
AGTCAATTCCCCCACCTCCTCACAGC-30 (nucleotides 2166 to
2131; position number þ 1 corresponding to the first nucleotide
of the transcription initiation site); reverse, 50-CCGCAATCCCA-
GAAAGCAGCCAAGTC-30 (nucleotides þ 965 to þ 990). The PCR
condition was an initial denaturation for 2 min at 951C, 30 cycles
(951C for 30 s, 481C for 30 s, and 721C for 4 min) and a final
extension at 721C for 8 min, with Ex Taq DNA polymerase (Takara,
Shiga, Japan) according to the manufacturer’s instructions. The
PCR products were subcloned into the pGEM-T vector (Promega,
Madison, Wisconsin). The obtained plasmid, designated as pTAh-
PAD2, was verified by restriction mapping and complete se-
quencing using a BigDye Terminator Cycle Sequencing Reaction
Kit (Applied Biosystems, Foster City, California) on automated DNA
sequencing (373 DNA Sequencer, Applied Biosystems).
RNase protection analysis To determine the 50 end of PADI2
mRNA, RNase protection analysis was performed as described by
Zhang et al (2001). To construct the template plasmid for synthesis
of the riboprobe, a PADI2 fragment containing the transcription
initiation site (132 to þ 167) was subcloned into the pT7Blue
vector (EMD Biosciences, Madison, Wisconsin). This DNA frag-
ment was prepared by PCR, using clone pTAhPAD2 as a template
with forward primer 50-CAGCGGGGCGGGACGAG-30 and reverse
primer 50-TAGACATCGGTCCAGAGGTAGGTG-30. The resulting
construct (pT7-PAD2) was linearized with BamHI, and anti-sense
RNA was synthesized with biotin labeling from the T7 promoter of
the plasmid using In Vitro Transcription Kit (BD Biosciences). Total
RNA (30 g) was obtained from NHEK cultured in the high-calcium
medium (1.2 mM) or HaCaT cells with an RNeasy Protect Kit (QIA-
GEN) and was hybridized to the anti-sense RNA for 16 h at 421C
using RPA Kit (BD Biosciences) according to the manufacturer’s
instructions. Salmon tRNA was used as a negative control. After
RNA samples were digested with an RNase mixture, the sizes of
protected RNAs were determined by a denaturing 5% (wt/vol) po-
lyacrylamide gel electrophoresis using a BD RiboQuant Non-Rad
Detection Kit (BD Biosciences). The reverse primer 50-labeled with
fluorescein isothiocyanate was used to perform the cDNA exten-
sion of the protected RNA segments using PowerScript Reverse
Transcriptase (BD Biosciences). Using pTAhPAD2 as the template
DNA, a sequence reaction was carried out using the Thermo Se-
quenase Cycle Sequencing Kit (USB, Cleveland, Ohio) and a 7 M
urea/10% polyacrylamide gel electrophoresis run for 2 h at 1500 V
Table I. Primers used for preparing the deletion mutants and oligonucleotides for the EMSA
Name Sequence Position
Primers for preparing the deletion constructs
G21947/1930 (forward) 50-TATCTCGAGCCCGGGGTCTCCGTCAG-30 1947/1930
G21080/1063 (forward) 50-TATCTCGAGGAGCTCCATCTTCCATC-30 1080/1063
G2435/420 (forward) 50-TATCTCGAGGTACCGGGCTGCACC-30 435/420
G2132/116 (forward) 50-TATCTCGAGCAGCGGGGCGGGACGAG-30 132/116
G2119/103 (forward) 50-TATCTCGAGCGAGTTAGGGGCGGGAC-30 119/103
G270/53 (forward) 50-TATCTCGAGAGAGGACTGGGGCGGGC-30 70/53
G254/38 (forward) 50-TATCTCGAGCCGCCCCGCCCACCGG-30 54/38
G241/25 (forward) 50-TATCTCGAGCCGGCCGCTGGATAAGG-30 41/25
G2RV (reverse) 50-TATAAGCTTCCTCCCCGCCGCAGTGC-30 þ 63/þ80
Oligonucleotides for the EMSA
Probe137/101S 50-GACCTCAGCGGGGCGGGACGAGTTAGGGGCGGGACCA-30 137/101
Probe135/98AS 50-GCGTGGTCCCGCCCCTAACTCGTCCCGCCCCGCTGAGG-30 135/98
Probe99/72S 50-GCTTGACGGACAGGCCCGCAGCCCACTG-30 99/72
Probe97/67AS 50-TCTCGCAGTGGGCTGCGGGCCTGTCCGTCAA-30 97/67
Probe66/41S 50-GGACTGGGGCGGGCCGCCCCGCCCAC-30 66/41
Probe64/36AS 50-GGCCGGTGGGCGGGGCGGCCCGCCCCAGT-30 64/36
Underline shows the recognition sequence for the restriction enzyme, XhoI or HindIII.
EMSA, electrophoretic mobility shift assay.
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with 1  TBE. The flush signal was detected through Flour Imager
595 system (Amersham Biosciences, Piscataway, New Jersey).
Construction of promoter reporter plasmids To construct the
reporter plasmid pG21947/þ 80, PCR was carried out using
pTAhPAD2 as a template and a pair of specific PADI2 primers, G2-
1947/1930 and G2-RV (Table I), at the following conditions: initial
denaturation at 951C for 1 min, 30 cycles (951C for 30 s, 551C for
30 s, and 721C for 4 min) and a final extension at 721C for 8 min.
The PCR product obtained was digested with XhoI and HindIII, and
cloned into the pGBasic vector 2 (Nippon Gene, Toyama, Japan),
which contains the firefly luciferase gene (LucF), but no regulatory
elements. Sequential 50-deletion constructs of the 50-flanking re-
gion of PADI2 were generated by PCR using pTAhPAD2 as a tem-
plate and the primers listed in Table I. The thermocycler settings
consisted of 2 min incubation at 951C, followed by 30 cycles at
951C for 30 s, 30 s at the predicted melting temperature for each
forward primer (Mitsuhashi et al, 1994) and 3 min at 721C, and a
final extension for 10 min at 721C. The resulting amplification
products were cloned into the XhoI and HindIII sites of pGBasic
vector 2. All of the constructs were prepared using the QIAfilter
Plasmid Midi Kit (QIAGEN), and their nucleotide sequences were
confirmed by double-stranded DNA sequencing.
Transfection and measurement of promoter activity Transfect-
ion experiments were carried out with two-passage cultured cells,
plated in 24-well tissue culture clusters at a density of 5  104
cells/well and transfected with 0.72 mg of each construct and
TransFast Transfection Reagent (Promega). To correct for
transfection efficiency, all cells were co-transfected with 0.03 mg
of pRL-SV40 vector, which contained the Renilla luciferase gene
(LucR) under the control of the SV40 promoter (Nippon Gene).
Unless specified, the cells were harvested 48 h after transfection,
and lysed with 100 mL of the reporter lysis buffer per well (Prome-
ga). Luciferase activities were analyzed with a PicaGene Dual
SeaPansy Luminescence Kit (Nippon Gene) and a Wallac 1420
ARVOsx Multilabel Counter (Perkin Elmer, Norwalk, Connecticut).
Firefly luciferase activity was normalized for Renilla luciferase ac-
tivity and expressed as ‘‘fold-induction’’ over the empty pGBasic
alone. Four transfections were carried out independently for each
construct, and the results were expressed as mean values.
EMSA The double-stranded oligonucleotides listed in Table I were
synthesized and labeled with [a-32P]dCTP using the Klenow frag-
ment of DNA polymerase I (Nippon Gene). We prepared three kinds
of the 32P-labeled double-stranded oligonucleotide probes made
up of the following pairs: Probe 137/101S and Probe 135/
98AS, Probe 99/72S and Probe 97/67AS, Probe 66/
41S and Probe 64/36AS. Nuclear extracts were prepared
from cultured cells as described by Andrews and Faller (1991).
Each reaction mixture (12.5 mL) containing 4 mg of nuclear proteins,
10 mM Hepes-KOH (pH 7.8), 50 mM KCl, 1 mM EDTA, 5 mM
MgCl2, 10% glycerol, 5 mM phenyl methyl sulfonyl floride, 25 ng
aprotinin, 25 ng pepstatin, 25 ng leupeptin, 1 mM sodium ortho-
vanadate, 2 mg poly (dI-dC), and 5 ng of 32P-labeled probe (1  105
cpm) was incubated at 271C for 30 min. For supershift experi-
ments, 2 mg of either anti-Sp1 or anti-Sp3 antibody (Santa Cruz
Biotechnology, Santa Cruz, California) was added to the binding
reaction mixture and incubated on ice for 20 min before addition of
the labeled probe. DNA-protein complexes were resolved by 4.5%
polyacrylamide gel electrophoresis in 0.25  TAE and then auto-
radiographed.
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